title: PCSK9 Inhibition: Does Lipoprotein Size Matter?
authors.affiliation: INSERM, UMR1087, l'institut du thorax, Nantes, France (K.S.T., B.C.) CNRS, UMR 6291, Nantes, France (K.S.T., B.C.) Université de Nantes, Nantes, France (K.S.T., B.C.).
authors.forename: Karim
authors.initials: K
authors.lastname: Si-Tayeb
authors.affiliation: INSERM, UMR1087, l'institut du thorax, Nantes, France (K.S.T., B.C.) CNRS, UMR 6291, Nantes, France (K.S.T., B.C.) Université de Nantes, Nantes, France (K.S.T., B.C.) CHU Nantes, l'institut du thorax, CIC Endocrinology-Nutrition, Nantes, France (B.C.).
authors.forename: Bertrand
authors.initials: B
authors.lastname: Cariou
mesh_terms: D008078:Cholesterol, LDL; D006801:Humans; D008074:Lipoproteins; D043484:Proprotein Convertases; D012697:Serine Endopeptidases
chemical_list: D008078:Cholesterol, LDL; D008074:Lipoproteins; D043484:Proprotein Convertases; D012697:Serine Endopeptidases
keywords: Editorials; PCSK9; diabetes mellitus; lipids and lipoproteins; low‐density lipoprotein‐cholesterol; low‐density lipoprotein‐particles; metabolic syndrome; monoclonal antibodies